The Week Ahead: Fed...
Health Care: Drugs
Athersys Inc. (ATHX: OTC)
$1.41 -0.07 | -4.73%
06/01/12 - 03:59 PM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 10.34M | 8.94M | 2.16M | 3.10M |
| Cost of Sales | -58.00K | -225.00K | -305.00K | -11.00K |
| Gross Operating Profit | 10.40M | 9.16M | 2.46M | 3.12M |
| Selling, General, and Administrative Expenses | 4.92M | 5.39M | 5.62M | 5.48M |
| Research & Development | 18.93M | 14.78M | 11.92M | 16.50M |
| Operating Income before D & A (EBITDA) | -13.44M | -11.00M | -15.08M | -18.86M |
| Depreciation & Amortization | 336.00K | 509.00K | 538.00K | 229.00K |
| Interest Income | 85.00K | 203.00K | 375.00K | 1.15M |
| Other Income - Net | -51.00K | -69.00K | -126.00K | 49.00K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -13.75M | -11.38M | -15.37M | -17.90M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 94.00K |
| Pre-Tax Income | -13.75M | -11.38M | -15.37M | -17.99M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -13.75M | -11.38M | -15.37M | -17.99M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -13.75M | -11.38M | -15.37M | -17.99M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -13.75M | -11.38M | -15.37M | -17.99M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-13.75M | -11.38M | -15.37M | -17.99M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -13.75M | -11.38M | -15.37M | -17.99M |
| Basic EPS from Continuing Ops. | -0.59 | -0.60 | -0.81 | -0.95 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.59 | -0.60 | -0.81 | -0.95 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.59 | -0.60 | -0.81 | -0.95 |
| Basic Normalized Net Income/Share | -0.59 | -0.60 | -0.81 | -0.95 |
| EPS fr Continuing Ops. | -0.59 | -0.60 | -0.81 | -0.95 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.59 | -0.60 | -0.81 | -0.95 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.59 | -0.60 | -0.81 | -0.95 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.59 | -0.60 | -0.81 | -0.95 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with ATHX
- Portfolio NameUser Type
- Contributor10 Cheap Biotech Stocks Tha...
- UserAlfa
- Contributor9 Health Care Stocks With 1...
- Contributor10 Pharma Stocks With 100% ...
- Contributor10 Biotech Stocks Expected ...
- UserFuture Speculation
- User©SUPRATRADE HOT STOCKS (...
- UserBesV Portfolio 1
- Userdawnf Portfolio 1
- UserMangar's picks
Latest ATHX Headlines from TheStreet
- Aastrom Raises Cash To Fund Pivotal Trial 03.09.12 | 12:03 pm
- Athersys Reports Fourth Quarter And 2010 Annual Results 03.14.11 | 04:03 pm
- Athersys Announces Initiation Of Patient Enrollment For Phase II Clinical Trial In Inflammatory Bowel Disease 03.14.11 | 07:03 am
- Athersys To Host Fourth Quarter Financial Results Call 02.18.11 | 07:02 am
- Researchers From UTHealth And Athersys Present Preclinical Data Illustrating Potential Benefits Of MultiStem(R) For Treating Stroke 02.10.11 | 07:02 am
- Athersys To Present At 13th Annual BIO CEO & Investor Conference 02.08.11 | 02:02 pm
- 10 Pharma Stocks With 100% Buy Ratings 02.03.11 | 11:02 am
- Athersys Announces Registered Direct Offering Of $13.1 Million 01.28.11 | 09:01 am
- Researchers From Case Western Reserve And Athersys Publish Landmark Study Showing Regenerative Benefit Of MultiStem Therapy After Spinal Cord Injury 01.19.11 | 07:01 am
- Athersys Announces Completion Of Patient Enrollment For Single Dose Arm Of Phase I Study Of MultiStem(R) For Hematopoietic Stem Cell Transplant Support 01.06.11 | 07:01 am
Press Releases for ATHX
- Athersys, Inc. - Retail Investor Conferences.com Presentation Now Available Online - PR Newswire 01.24.11 | 12:01 pm
- RTI Biologics And Athersys Announce Collaboration In The Orthopedic Market - Business Wire 09.13.10 | 07:09 am
Partner Headlines for ATHX
- Follow the Analyst Leader: New Stock Coverage to Watch - Wall St. Cheat Sheet 05.31.12 | 04:05 am
- Microcap Movers for Friday December 2 , 2011 - Benzinga 12.02.11 | 05:12 pm
- Zacks #5 Rank Additions for Thursday - Tale of the Tape - Zacks 09.29.11 | 09:09 am
- Zacks #5 Rank Additions for Friday - Tale of the Tape - Zacks 09.23.11 | 09:09 am
- Zacks #5 Rank Additions for Wednesday - Tale of the Tape - Zacks 08.31.11 | 09:08 am
- Zacks #5 Rank Additions for Friday - Tale of the Tape - Zacks 08.26.11 | 09:08 am
- Zacks #5 Rank Additions for Friday - Tale of the Tape - Zacks 08.12.11 | 09:08 am
- Athersys Q2 Loss Is Slight Improvement Over Previous Year - Seeking Alpha 08.11.11 | 09:08 am
- Zacks #5 Rank Additions for Tuesday - Tale of the Tape - Zacks 05.10.11 | 09:05 am
- 4 Biotech Companies That Could Be Buyout Targets - Seeking Alpha 04.05.11 | 08:04 am
